|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13G
|
UNDER THE SECURITIES EXCHANGE ACT OF 1934
|
(Amendment No. 1)*
|
ProQR Therapeutics N.V. (Name of Issuer) |
Ordinary Shares, nominal value EUR0.04 per share (Title of Class of Securities) |
(CUSIP Number) |
07/15/2026 (Date of Event Which Requires Filing of this Statement) |
| Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
 Rule 13d-1(b)
|
 Rule 13d-1(c)
|
| Rule 13d-1(d)
|
SCHEDULE 13G
|
| CUSIP No. |
| 1 | Names of Reporting Persons
STICHTING AESCAP LIFE SCIENCES | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
NETHERLANDS
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
4,156,878.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
2.95 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
FI |
Comment for Type of Reporting Person: (1) Based upon 141,121,476 ordinary shares outstanding
SCHEDULE 13G
|
| CUSIP No. |
| 1 | Names of Reporting Persons
PRIVIUM FUND MANAGEMENT B.V. | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
NETHERLANDS
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
5,467,149.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
3.87 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
FI |
Comment for Type of Reporting Person: (1) Based upon 141,121,476 ordinary shares outstanding
SCHEDULE 13G
|
| CUSIP No. |
| 1 | Names of Reporting Persons
STICHTING AESCAP GENETICS | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
NETHERLANDS
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
1,310,271.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
0.93 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
FI |
Comment for Type of Reporting Person: (1) Based upon 141,121,476 ordinary shares outstanding
SCHEDULE 13G
|
| CUSIP No. |
| 1 | Names of Reporting Persons
INSPIRATIONAL VISIONS B.V. | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
NETHERLANDS
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
35,411.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
0.03 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
FI |
Comment for Type of Reporting Person: (1) Based upon 141,121,476 ordinary shares outstanding
SCHEDULE 13G
|
| CUSIP No. |
| 1 | Names of Reporting Persons
PATRICK JOHAN HENDRIK KROL | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
NETHERLANDS
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
5,528,862.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
5.2 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
FI |
Comment for Type of Reporting Person: (1) Based upon 141,121,476 ordinary shares outstanding
SCHEDULE 13G
|
| Item 1. | ||
| (a) | Name of issuer:
ProQR Therapeutics N.V. | |
| (b) | Address of issuer's principal executive offices:
Zernikedreef 9, Leiden, The Netherlands CK 2333 | |
| Item 2. | ||
| (a) | Name of person filing:
(i) Stichting Aescap Life Sciences ("Aescap Life Sciences")
(ii) Privium Fund Management B.V. ("Privium"), as the fund manager of Aescap Life Sciences
(iii) Stichting Aescap Genetics ("Aescap Genetics")
(iv) Inspirational Visions BV ("Inspirational Visions")
(v) Patrick Johan Hendrik Krol ("Krol"), the portfolio manager for Privium regarding Aescap Life Sciences and Aescap Genetics and the managing director of Inspirational Visions
The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." | |
| (b) | Address or principal business office or, if none, residence:
The principal business address of each of Aescap Life Sciences, Privium, Aescap Genetics and Krol is:
Gustav Mahlerplein 3
1082 MS Amsterdam
The Netherlands
The principal business address of Inspirational Visions is:
A.J. Ernststraat 595-C
1082 LN Amsterdam
The Netherlands | |
| (c) | Citizenship:
The citizenship of each of the Reporting Persons is the Netherlands. | |
| (d) | Title of class of securities:
Ordinary Shares, nominal value EUR0.04 per share | |
| (e) | CUSIP No.:
| |
| Item 3. | If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: | |
| (a) | Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
| |
| (b) | Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
| |
| (c) | Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
| |
| (d) | Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
| |
| (e) | An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
| |
| (f) | An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
| |
| (g) | A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
| |
| (h) | A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
| |
| (i) | A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
| |
| (j) | A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution: | |
| (k) | Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
| |
| Item 4. | Ownership | |
| (a) | Amount beneficially owned:
As its Fund Manager, the Shares held by Aescap Life Sciences may be deemed to be beneficially
owned by Privium. In addition, as its Fund Manager, the Shares held by Aescap Genetics may be
deemed to be beneficially owned by Privium. As the portfolio manager of Privium, Krol may be deemed
to beneficially own the Shares held by Aescap Life Sciences and Aescap Genetics. In addition, as the
managing director of Inspirational Visions, Krol may be deemed to beneficially own the Shares held by
Inspirational Visions.
As of the date of this report, Aescap Life Sciences directly held 4,156,878 Shares. As of the date of this
report, Aescap Genetics directly held 1,310,271 Shares. As of the date of this report, Inspirational
Visions directly held 35,411 Shares. As of the date of this report, Krol directly held 26,302 Shares. | |
| (b) | Percent of class:
Aescap Life Sciences may be deemed the beneficial owner of approximately 2.95% of the Shares outstanding.
Privium may be deemed the beneficial owner of approximately 3.87% of the Shares outstanding.
Aescap Genetics may be deemed the beneficial owner of approximately 0.93% of the Shares outstanding.
Inspirational Visions may be deemed the beneficial owner of approximately 0.03% of the Shares outstanding.
Krol may be deemed the beneficial owner of approximately 3.92% of the Shares outstanding. %
| |
| (c) | Number of shares as to which the person has:
| |
| (i) Sole power to vote or to direct the vote:
Aescap Life Sciences: 4,156,878
Privium: 5,467,149
Aescap Genetics: 1,310,271
Inspirational Visions: 35,411
Krol: 5,528,862 | ||
| (ii) Shared power to vote or to direct the vote:
Aescap Life Sciences: 0
Privium: 0
Aescap Genetics: 0
Inspirational Visions: 0
Krol: 0 | ||
| (iii) Sole power to dispose or to direct the disposition of:
Aescap Life Sciences: 4,156,878
Privium: 5,467,149
Aescap Genetics: 1,310,271
Inspirational Visions: 35,411
Krol: 5,528,862 | ||
| (iv) Shared power to dispose or to direct the disposition of:
Aescap Life Sciences: 0
Privium: 0
Aescap Genetics: 0
Inspirational Visions: 0
Krol: 0 | ||
| Item 5. | Ownership of 5 Percent or Less of a Class. | |
| Item 6. | Ownership of more than 5 Percent on Behalf of Another Person. | |
Not Applicable
| ||
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. | |
Not Applicable
| ||
| Item 8. | Identification and Classification of Members of the Group. | |
Not Applicable
| ||
| Item 9. | Notice of Dissolution of Group. | |
Not Applicable
| ||
| Item 10. | Certifications: |
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. |
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|
|
|
|
|
|
|
Exhibit Information
|
Exhibit 99.1: Joint Filing Agreement (filed herewith). |
Exhibit 99.1
Joint Filing Agreement
The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained herein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate.
Date: July 15, 2026
| STICHTING AESCAP LIFE SCIENCES | ||
| BY: PRIVIUM FUND MANAGEMENT B.V., ITS FUND MANAGER | ||
| By: | /s/ P.J.H. Krol | |
| Name: | P.J.H. Krol | |
| Title: | Portfolio Manager | |
| STICHTING AESCAP GENETICS | ||
| BY: PRIVIUM FUND MANAGEMENT B.V., ITS FUND MANAGER | ||
| By: | /s/ P.J.H. Krol | |
| Name: | P.J.H. Krol | |
| Title: | Portfolio Manager | |
| PRIVIUM FUND MANAGEMENT B.V. | ||
| By: | /s/ P.J.H. Krol | |
| Name: | P.J.H. Krol | |
| Title: | Portfolio Manager | |
| INSPIRATIONAL VISIONS B.V. | ||
| By: | /s/ P.J.H. Krol | |
| Name: | P.J.H. Krol | |
| Title: | Managing Director | |
| PATRICK JOHAN HENDRIK KROL | ||
| /s/ P.J.H. Krol | ||
| Dated: July 15, 2026 | ||